Handling and Reporting of Biopsy and Surgical Specimens of Testicular Cancer

European Urology

Volumn 45, Issue 5, 2004, Pages 564-573

  Winstanley, A M ^a,e   Mikuz, G ^b   Debruyne, F ^c   Schulman, C C ^d   Parkinson, M C ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ERASME HOSPITAL   (Belgium)

^e UCL ^*  (United Kingdom)

Author keywords

Germ cell tumour; Lymphadenectomy; Protocol; Testis

Indexed keywords

CALRETININ; CD30 ANTIGEN; CYTOKERATIN; INHIBIN; MELAN A;

CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RISK; CRYPTORCHISM; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FROZEN SECTION; GERM CELL TUMOR; GONADAL DYSGENESIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHADENECTOMY; LYMPHOMA; MALE INFERTILITY; MEDICAL AUDIT; MEDICAL RECORD; MICROSCOPY; ORCHIECTOMY; PATHOLOGIST; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEMINOMA; SEX CORD TUMOR; TESTIS BIOPSY; TESTIS CANCER; TISSUE FIXATION; TRUE HERMAPHRODITISM; TUMOR BIOPSY; UROLOGY;

BIOPSY; FROZEN SECTIONS; HUMANS; LYMPH NODE EXCISION; MALE; MEDICAL RECORDS; ORCHIECTOMY; SPECIMEN HANDLING; TESTICULAR NEOPLASMS;

EID: 1842788116     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2003.10.015     Document Type: Review

References (87)

1. Harland S.J., Cook P.A., Fossa S.D.et al. Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. J. Urol. 160(4):1998;1353-1357.
2. Mostofi F.K., Sesterhenn IA. Histological typing of testis tumours. 2nd ed. Berlin: Springer-Verlag; 1998.
3. Pryor J.P., Cameron K.M., Chilton C.P.et al. Carcinoma in situ in testicular biopsies from men presenting with infertility. Br. J. Urol. 55(6):1983;780-784.
4. Bettocchi C., Coker C.B., Pryor J.P. The importance of biopsy in primary testicular failure. J. Androl. 15(Suppl 1):1994;14S-16S.
5. Loy V., Dieckmann K.P. Prevalence of contralateral testicular intraepithelial neoplasia (carcinoma in situ) in patients with testicular germ cell tumours: results of the German multicentre study. Eur. Urol. 23(1):1993;120-122.
6. Heidenreich A., Moul J.W. Contralateral testicular biopsy procedure in patients with unilateral testis cancer: is it indicated. Semin. Urol. Oncol. 20(4):2002;234-238.
7. von der Maase H., Rorth M., Walbom-Jorgensen S.et al. Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. Br. Med. J. (Clin. Res. Ed.). 293(6559):1986;1398- 1401.
8. Dieckmann K.P., Bresserer A., Loy V. Low-dose radiation therapy for testicular intraepithelial neoplasia. J. Cancer Res. Clin. Oncol. 119(6):1993;355-359.
9. Petersen P.M., Giwercman A., Daugaard G.et al. Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. J. Clin. Oncol. 20(6):2002;1537-1543.
10. Dieckmann K.P., Lauke H., Michl U., Winter E., Loy V. Testicular germ cell cancer despite previous local radiotherapy to the testis. Eur. Urol. 41(6):2002;643-649.
11. Classen J., Dieckmann K., Bamberg M.et al. Radiotherapy with 16 Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose reduction trial of the German Testicular Cancer Study Group. Br. J. Cancer. 88(6):2003;828-831.
12. Albers P., Goll A., Bierhoff E.et al. Clinical course and histopathologic risk factor assessment in patients with bilateral testicular germ cell tumours. Urology. 54(4):1999;714-718.
13. Kristianslund S., Fossa S.D., Kjellevold K. Bilateral malignant testicular germ cell cancer. Br. J. Urol. 58(1):1986;60-63.
14. Dieckmann K.P., Souchon R., Hahn E.et al. False-negative biopsies for testicular intraepithelial neoplasia. J. Urol. 162(2):1999;364-368.
15. Dieckmann K.P., Loy V. False-negative biopsies for the diagnosis of testicular intraepithelial neoplasia (TIN) - an update. Eur. Urol. 43(5):2003;516-521.
16. Dieckmann K.P., Classen J., Loy V. Diagnosis and management of testicular intraepithelial neoplasia (carcinoma in situ) - surgical aspects. APMIS. 111(1):2003;64-68.
17. Herr H.W., Sheinfeld J. Is biopsy of the contralateral testis necessary in patients with germ cell tumours. J. Urol. 158(4):1997;1331-1334.
18. Morey A.F., MacDonald M.F., Rozanski T.A.et al. Yield and efficacy of biopty gun testis needle biopsy. Urology. 53(3):1999;604-607.
19. Apaydm E., Semerci B., Iibey O.et al. Use of new automated biopsy device for percutaneous testicular biopsy. A preliminary clinical experience. Arch. Ital. Urol. Androl. 70(1):1998;19-21.
20. Cohen M.S., Frye S., Warner R.S.et al. Testicular needle biopsy in diagnosis of infertility. Urology. 24(5):1984;439-442.
21. Arnold M.M., Srivastava S., Fredenburgh J., Stockard C.R.et al. Effects of fixation and tissue processing on immunohistochemical demonstration of specific antigens. Biotech. Histochem. 71(5):1996;224-230.
22. Jacobsen M., Jacobsen G.K. The influence of various fixatives on the immunohistochemical demonstration of a number of plasma proteins and oncofetal proteins in paraffin embedded material. Acta Pathol. Microbiol. Immunol. Scand. 92(6):1984;461-468.
23. Latendresse J.R., Warbrittion A.R., Jonassen H.et al. Fixation of testes and eyes using a modified Davidson's fluid comparison with Bouin's fluid and conventional Davidson's fluid. Toxicol. Pathol. 30(4):2002;524-533.
24. Skakkebaek N.E. Possible carcinoma in-situ of the testis. Lancet. 2:1972;516-517.
25. Johnsen S.G. Testicular biopsy score count - a method for registration of spermatogenesis in human testes: normal values and results in 335 hypogonadal males. Hormones. 1:1970;2-25.
26. Burke A.P., Mostofi F.K. Placental alkaline phosphatase immunohistochemistry of intratubular malignant germ cells and associated testicular germ cell neoplasia. Human Pathol. 19:1988;663-670.
27. Giwercman A., Cantell L., Marks A. Placental-like alkaline phosphatase as a marker of carcinoma in-situ of the testis. Comparison with monoclonal antibodies M2A and 43-9F. APMIS. 99:1991;586-594.
28. Dieckmann K.P., Skakkebaek N.E. Carcinoma in situ of the testis: review of biological and clinical features. Int. J. Cancer. 83(6):1999;815-822.
29. Izquiderdo M.A., van der Valk P., van Ark-Otte J.et al. Differential expression of the c-kit proto-oncogene in germ cell tumours. J. Pathol. 177(3):1995;253-258.
30. Rajpert-De Meyts E., Skakkebaek N.E. Expression of the c-kit protein product in carcinoma-in-situ and invasive testicular germ cell tumours. Int. J. Androl. 17(2):1994;85-92.
31. Tokuc R., Sakr W., Pontes J.E.et al. Accuracy of frozen section examination of testicular tumours. Urology. 40(6):1992;512-516.
32. Elert A., Olbert P., Hegele A., Barth P., Hofmann R., Heidenreich A. Accuracy of frozen section examination of testicular tumors of uncertain origin. Eur. Urol. 41(3):2002;290-293.
33. Heidenreich A., Weissbach L., Holtl W.et al. Organ sparing surgery for malignant germ cell tumour of the testis. J. Urol. 166(6):2001;2161-2165.
34. Hopps C.V., Goldstein M. Ultrasound guided needle localisation and microsurgical exploration for incidental nonpalpable testicular tumours. J. Urol. 168(3):2002;1084-1087.
35. Leroy X., Rigot J.M., Aubert S.et al. Value of frozen section examination for the management of nonpalpable incidental testicular tumours. Eur. Urol. 44(4):2003;458-460.
36. Parkinson M.C. Differential diagnosis of a testicular mass in an adult. Adv. Clin. Path. 4(4):2000;222-226.
37. The Royal College of Pathologists. Standards and minimum datasets for reporting common cancers. Minimum dataset for testicular tumour histopathology reports. 2000.
38. Sternberg C.N. The management of stage I testis cancer. Urol. Clin. North Am. 25:1998;435-449.
39. Ford T.F., Parkinson M.C., Pryor J.P. The undescended testis in adult life. Br. J. Urol. 57(2):1985;181-184.
40. Ramani P., Yeung C.K., Habeebu S.S. Testicular intratubular germ cell neoplasia in children and adolescents with intersex. Am. J. Surg. Pathol. 17(11):1993;1124-1133.
41. Ulbright TA, Amin MA, Young RH. Atlas of tumour pathology. Third series. Fasicle 25. Tumours of the testis, adenexa, spermatic cord and scrotum. Washington DC: American Forces Institute of Pathology; 1999.
42. Pugh RCB. Testicular tumours - introduction. In: Pugh RCB, editor. Pathology of the testis. 1st edition. Oxford: Blackwell Scientific Publications; 1976. Chapter 4.
43. Mostofi FK, Sesterhenn IA. Histological typing of testis tumours. In: WHO International Classification of Tumours. 2nd edition. Berlin: Springer; 1998.
44. Eble JN, Sauter G, Epstein J, Sesterhenn I, editors. World Health Organisation Classification of Tumours, Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; in press.
45. Henson D.E., Fielding P., Grignon D.J.et al. College of American Pathologists XXVI Conference on Clinical Relevance of Prognostic Markers in Solid Tumours. Arch. Pathol. Lab. Med. 119:1995;1109-1112.
46. Lashley D.B., Lowe B.A. A rational approach to managing stage I non-seminomatous germ cell tumours. Urol. Clin. North Am. 25:1998;405-423.
47. Frohlich M.W., Small E.J. Stage II non-seminomatous testis cancer: the roles of primary and adjuvant chemotherapy. Urol. Clin. North Am. 25:1998;451-459.
48. Freedman L.S., Parkinson M.C., Jones W.G.et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet. 2(8554):1987;294-298.
49. Read G, Stenning SP, Cullen MH. et al. Medical research council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 10(11):1762-8.
50. Fung C.Y., Kalish L.A., Brodsky G.L.et al. Stage I nonseminomatous germ cell testicular tumour: predictors of metastatic potential by primary histopathology. J. Clin. Oncol. 6(9):1988;1467-1473.
51. Toner G.C., Motzer R.J. Poor prognosis germ cell tumours: current status and future directions. Semin. Oncol. 25(2):1998;194-202.
52. Albers P., Bierhoff E., Neu D.et al. MIB-1 immunohistochemistry in clinical stage I non-seminomatous testicular germ cell tumours predicts patients at low risk for metastasis. Cancer. 79:1997;1710-1716.
53. Albers P., Miller G.A., Orazi A.et al. Immunohistochemical assessment of tumour proliferation and volume of embryonal carcinoma identified patients with clinical stage I non-seminomatous testicular germ cell tumour at low risk of occult metastases. Cancer. 75:1995;844-850.
54. Warde P., Specht L., Horwich A.et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J. Clin. Oncol. 20(22):2002;4448-4452.
55. Jacobsen G.K., von der Maase H., Specht L.et al. Histopathological features of stage I seminoma treated with orchidectomy only. J. Urol. Pathol. 3:1995;85-94.
56. Warde P., Gospodarowicz M.K., Banerjee D.et al. Prognostic factors for relapse in stage I testicular seminoma treated with surveillance. J. Urol. 157:1997;1705-1710.
57. Warde P., von der Maase H., Horwich A.et al. Prognostic factors for relapse in stage I seminoma managed by surveillance. Clinic Oncol. 17:1998;309a.
58. Von der Maase H., Specht L., Jacobsen G.K.et al. Surveillance following orchidectomy for Stage I seminoma of the testis. Eur. J. Cancer. 29a:1993;1931-1934.
59. Horwich A., Alsanjari N., A'hern R.et al. Surveillance following orchidectomy for stage I testicular seminoma. Br. J. Cancer. 65:1992;775-778.
60. Gospodarowicz M.K., Warde P.R., Panzarella T. The Princess Margaret Hospital experience in the management of stage I and stage II Seminoma - 1981-91. Adv. Biosci. 91:1994;177-185.
61. Warde P, Gospodarowicz MK, Panzarella T. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 1995;2255-62.
62. Kim I., Young R.H., Scully R.E. Leydig cell tumours of the testis. A clinicopathological analysis of 40 cases and review of the literature. Am. J. Surg. Pathol. 9(3):1985;177-192.
63. McCluggage W.G., Shanks J.H., Arthur K.et al. Cellular proliferation and nuclear ploidy assessments augment established prognostic factors in predicting malignancy in testicular Leydig cell tumours. Histopathology. 33(4):1998;361-368.
64. Feitz W.F., Debruyne F.M., Ramaekers F.C. Intermediate filament proteins as tissue specific markers in normal and neoplastic tissue. Int. J. Androl. 10(1):1987;51-56.
65. Cheville J.C., Roa S., Iczkowski K.A.et al. Cytokeratin expression in seminoma of the human testis. Am. J. Clin. Pathol. 113(4):2000;583-588.
66. Parkinson M.C., Harland S.J., Harnden P.et al. The role of the histopathologist in the management of testicular germ cell tumour in adults. Histopathology. 38:2001;183-194.
67. Kraggerud S.M., Berner A., Bryne M.et al. Spermatocytic seminoma as compared to classical seminoma: an immunohistochemical and DNA flow cytometric study. APMIS. 107(3):1999;297-302.
68. Pera M.F., Bennett W., Cerretti D.P. CD30 and its ligand: possible role in regulation of teratoma stem cells. APMIS. 106:1998;169-173.
69. Hittmair A., Rogatsch H., Hobisch A.et al. CD30 expression in seminoma. Hum. Pathol. 27(11):1996;1166-1171.
70. Bergh A., Cajander S. Immunohistochemical localization of inhibin-alpha in the testis of normal men and in men with testicular disorders. Int. J. Androl. 13(6):1990;463-469.
71. Augusto D., Leteurtre E., De La Taille A.et al. Calretinin: a valuable marker of normal and neoplastic Leydig cells of the testis. Appl. Immunohistochem Mol. Morphol. 10(2):2002;159-162.
72. Busam K.J., Iversen K., Coplan K.A.et al. Immunoreactivity for A103, an antibody to melan-A (Mart-1) in adrenocortical and other steroid tumours. Am. J. Surg. Pathol. 22(1):1999;57-63.
73. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organisation Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press.
74. Preiner J.L., Jewett M.A. Role for retroperitioneal lymphadenectomy for testis cancer. Curr. Opin. Urol. 9(3):1999;205-208.
75. Hendry W.F., Norman A.R., Dearnaley D.P.et al. Metastatic nonseminomatous germ cell tumours of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer. 94(6):2002;1668-1676.
76. Michael H., Lucia J., Foster R.S.et al. The pathology of late recurrences of testicular germ cell tumours. Am. J. Surg. Path. 24:2000;257-273.
77. Stenning S.P., Parkinson M.C., Fischer C.et al. Post chemotherapy residual masses in germ cell tumour patients. Cancer. 83:1998;1409-1419.
78. Steyerberg E.W., Keizer H.J., Messemer J.E.et al. Residual pulmonary masses after chemotherapy for metastatic non-seminomatous germ cell tumour: prediction of histology. Cancer. 79:1997;345-355.
79. Tiffany P., Morse M.J., Bosl G.et al. Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumours. Cancer. 57:1986;978-983.
80. Toner G.C., Panicek D.M., Heelan R.J.et al. Adjuvant surgery after chemotherapy for non-seminomatous germ cell tumours: recommendations for patient selection. J. Clin. Oncol. 8:1990;1683-1694.
81. Qvist H.L., Fossa S.D., Ous S.et al. Post-chemotherapy tumour residuals in patients with advanced non-seminomatous testicular cancer: is it necessary to resect all residual masses? J. Urol. 145:1991;300-303.
82. Sheinfeld J. The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumours: current concepts and controversies. Semin. Urol. Oncol. 20(4):2002;262-271.
83. Gerl A., Clemm C., Schmeller N.et al. Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumour. Br. J. Cancer. 70:1994;960-965.
84. Brenner P.C., Herr H.W., Morse M.J.et al. Simultaneous retroperitoneal, thoracic and cervical resection of post-chemotherapy residual masses in patients with metastatic non-seminomatous germ cell tumour of the testis. J. Clin. Oncol. 14:1996;1765-1769.
85. Tognini P.G., Foster R.S., McGraw P.et al. Combined post chemotherapy retroperitoneal lymph node dissection and resection of chest tumour under the same anaesthetic is appropriate based on morbidity and tumour pathology. J. Urol. 159:1998;1833-1835.
86. Einhorn L.H. Do all germ cell tumour patients with residual masses in multiple sites require post-chemotherapy resections. J. Clin. Oncol. 15:1997;409.
87. Sobin LH, Wittekind C. TNM classification of malignant tumours. 6th ed. International Union Against Cancer. New York Wiley-Liss; 2002.